Furthermore, the upregulation of alternative immune checkpoints, such as LAG-3, TIGIT, B and T lymphocyte attenuator (BTLA), and TIM-3, can further suppress the immune response and enable tumor progression despite ongoing ICI therapy [271–273]. Here, HAVCR2 is linked to neoplasm.